Battisti et al., in a retrospective study of HER2-positive breast cancer patients, reported a lower incidence (5.9%) of LVEF decline, although their cohort included a substantial proportion (43.1%) of low-risk patients [27]. The gene discussed is ERBB2; the disease is breast carcinoma.